Connection

Michael Lilly to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications Michael Lilly has written about Xenograft Model Antitumor Assays.
  1. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma. Oncotarget. 2016 Dec 13; 7(50):83514-83529.
    View in: PubMed
    Score: 0.034
  2. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52.
    View in: PubMed
    Score: 0.031
  3. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis. 2014 Oct; 35(10):2321-30.
    View in: PubMed
    Score: 0.029
  4. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia. 2011 Feb; 13(2):108-19.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.